Merck Zepatier (Elbasvir/Grazoprevir) Drug Interaction Quick Guide for Clinicians

Elbasvir/grazoprevir (Zepatier™) is a hepatitis C virus (HCV) medication used to treat chronic hepatitis C. The medication works by inhibiting viral replication. Elbasvir and grazoprevir are substrates of CYP3A4 and P-glycoprotein (P-gp). Coadministration with moderate or strong CYP3A4 inhibitors or inducers is likely to result in interactions. Grazoprevir is a substrate of OATP1B1/3 transporters. Coadministration with medications that inhibit OATP1B1/3 should be avoided.


Merck Zepatier (Elbasvir/Grazoprevir) Drug Interaction Quick Guide for Clinicians - cover page
Brand
Merck
Category
Drugs
Document type
Product Leaflet
Language
English
Pages
3
File format
PDF
File size
86 KB
Published
24 November, 2023
Updated
24 November, 2023
MD5 checksum
69FD5E72F28792A61F61BCB2332F5841

About this manual

This three-page quick guide for clinicians summarizes the mechanism of action, route of metabolism, and drug interaction potential of elbasvir/grazoprevir (Zepatier™) for hepatitis C treatment. It lists recommendations for concurrent use with HIV protease inhibitors, non-nucleoside reverse transcriptase inhibitors, integrase strand transfer inhibitors, entry inhibitors, and nucleoside/nucleotide reverse transcriptase inhibitors.

The guide also covers common primary care medications, including antibiotics, anticonvulsants, antifungals, antimycobacterials, endothelin antagonists, herbal products, HMG-CoA reductase inhibitors, immunosuppressants, and wakefulness-promoting agents, with dosing limits and monitoring notes where stated.

What's inside

  • Mechanism of Action and Route of Metabolism
  • HIV Protease Inhibitors
  • HIV Non Nucleoside Reverse Transcriptase Inhibitors
  • HIV Integrase Strand Transfer Inhibitors
  • HIV Entry Inhibitors
  • HIV Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
  • Common Primary Care Medications
  • Statin Dosing Limits
  • Immunosuppressants
  • Disclaimer

Specifications

Medication classNS5a inhibitor and NS3/4A protease inhibitor
CYP3A4 and P-gp statusElbasvir and grazoprevir are substrates of CYP3A4 and P-glycoprotein (P-gp)
OATP1B1/3 statusGrazoprevir is a substrate of OATP1B1/3 transporters
Atorvastatin maximum dose with concurrent use20 mg daily
Rosuvastatin maximum dose with concurrent use10 mg daily

Frequently asked questions

What is the mechanism of action of elbasvir/grazoprevir (Zepatier™)?

Elbasvir/grazoprevir is an NS5a inhibitor and NS3/4A protease inhibitor used for HCV.

Can elbasvir/grazoprevir be co-administered with ritonavir-boosted HIV protease inhibitors?

No. Co-administration is not recommended because of potential hepatotoxicity and increased grazoprevir plasma concentrations.

Which HIV regimens containing cobicistat are not recommended with elbasvir/grazoprevir?

Elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine (Stribild®) and elvitegravir/cobicistat/tenofovir alafenamide/emtricitabine (Genvoya®) are not recommended because cobicistat is likely to increase elbasvir and grazoprevir concentrations.

What statin dose limits apply when using statins with elbasvir/grazoprevir?

Do not exceed atorvastatin 20 mg daily or rosuvastatin 10 mg daily. For fluvastatin, lovastatin, and simvastatin, use the lowest doses and titrate with close monitoring.

Download PDF (86 KB)

More Merck Manuals


View all Merck manuals →